Skip to content

ICAAC: Pilot study shows dual protease inhibitor regimen as safe and effective as traditional two class HIV therapy

ICAAC: New treatment for lipid problems shows promise in HIV patients

ICAAC: TB patients with good CD4 cell counts can safely defer HIV treatment

Improving the diagnosis of active TB in people with HIV

ICAAC: Early trials involving new GSK protease inhibitor have encouraging results

ICAAC: Nevirapine still present in breastmilk two weeks after last dose

ICAAC: Achillion reveals potential for once weekly dosing of nucleoside analogue

South African study finds many patients die waiting for treatment after enrolment into antiretroviral rollout programme

ICAAC: No added benefit from adding AZT to nevirapine to prevent MTCT